TAK N Stock Overview
Engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Takeda Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥287.95 |
| 52 Week High | JP¥293.20 |
| 52 Week Low | JP¥231.51 |
| Beta | 0.47 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -0.71% |
| 5 Year Change | -25.21% |
| Change since IPO | -7.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| TAK N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | -0.4% |
| 1Y | n/a | -27.2% | -14.8% |
Return vs Industry: Insufficient data to determine how TAK N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TAK N performed against the MX Market.
Price Volatility
| TAK N volatility | |
|---|---|
| TAK N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in MX Market | 6.0% |
| 10% least volatile stocks in MX Market | 2.7% |
Stable Share Price: TAK N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine TAK N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1781 | 49,281 | Christophe Weber | www.takeda.com |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
Takeda Pharmaceutical Company Limited Fundamentals Summary
| TAK N fundamental statistics | |
|---|---|
| Market cap | Mex$859.46b |
| Earnings (TTM) | Mex$38.02b |
| Revenue (TTM) | Mex$596.09b |
22.6x
P/E Ratio1.4x
P/S RatioIs TAK N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TAK N income statement (TTM) | |
|---|---|
| Revenue | JP¥4.55t |
| Cost of Revenue | JP¥1.55t |
| Gross Profit | JP¥3.00t |
| Other Expenses | JP¥2.71t |
| Earnings | JP¥290.00b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | 182.94 |
| Gross Margin | 65.95% |
| Net Profit Margin | 6.38% |
| Debt/Equity Ratio | 73.0% |
How did TAK N perform over the long term?
See historical performance and comparisonDividends
4.7%
Current Dividend Yield104%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/15 05:55 |
| End of Day Share Price | 2024/09/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Takeda Pharmaceutical Company Limited is covered by 38 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hazim Bahari | CFRA Equity Research |